Zion Pharma Starts US Trial of Treatment for Breast Cancer Brain Metastases

Zion Pharma, headquartered in Hong Kong , has started a US Phase I trial of its novel HER2 inhibitor that is designed to address brain metastases of HER2+ breast cancer. Founded in 2018, Zion says it uses its DMPK expertise to develop candidates with best-in-class potential to inhibit cancer, especially those that cross the blood-brain barrier. The trial is being conducted at US sites that include the Dana Farber Cancer Institute and the Duke Cancer Institute. Zion has research operations in Shanghai and Suzhou . More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.